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Minodronic acid (YM529) is a third-generation bisphosphonate (BP) that has been shown to directly and indirectly prevent
proliferation, induce apoptosis, and inhibit metastasis of various types of cancer cells. In this study, we have investigated the
therapeutic efficacy of YM529 against bladder cancer, both in vitro and in vivo. YM529 inhibited geranylgeranylation as well as
farnesylation and reduced the growth of all seven bladder cancer cell lines in a dose- and time-dependent manner in vitro. YM529
demonstrated a good synergistic or additive antiproliferative effect when administered in combination with cisplatin or paclitaxel.
Immunohistochemical study revealed YM529 inhibited the prenylation of Rap1A in vivo. YM529 administered systemically did not
markedly inhibit the growth of visceral metastases but it showed a significant anticancer effect on bone metastases monitored by an in
vivo imaging system. Moreover, intravesical YM529 demonstrated significant growth inhibition in a bladder cancer orthotopic model.
No adverse effects were associated with the systemic as well as the intravesical treatment regimens. In conclusion, our study suggests
that YM529 may be a potent anticancer agent for bladder cancer. The efficacy and safety of this BP as an agent for combination
chemotherapies against bladder cancer should be verified by early-phase clinical trials.
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Bladder cancer is the fifth most common solid malignancy in the
United States. It is estimated that in 2004 there would be 60240
new cases of and 12710 deaths from bladder cancer in the United
States (Jemal et al, 2004). Although 70% of bladder cancers are
superficial at presentation and able to be managed by transurethral
resection, 60–70% of superficial tumours recur and 20–30% of
recurrent disease progresses to higher stages or grades (Messing,
2001; Gee et al, 2002). Radical cystectomy is the standard
treatment for operable invasive bladder cancer, and the combina-
tion of methotrexate, vinblastine, doxorubicin, and cisplatin
(MVAC) chemotherapy is the common therapeutic option for
distant metastases (Dreicer, 2001; Messing, 2001). The metastatic
sites of bladder cancer are lung, liver, and bone in order of
preference (Babaian et al, 1980). Although bladder cancer is a
chemosensitive tumour, most deaths from bladder cancer are
caused by invasion and subsequent metastases that are resistant to
conventional chemotherapy (Dreicer, 2001; Hussain and James,
2003). In order to improve the outcome for patients with advanced
bladder cancer, the development of novel therapeutic options are
mandatory.
Bisphosphonate (BP) is an inhibitor of bone-resorption and has
been shown to directly and indirectly prevent proliferation, induce
apoptosis, and inhibit metastasis of various types of cancer cells
(Kuroda et al, 2003; Green, 2004; Santini et al, 2006). Bispho-
sphonates inhibit farnesyl pyrophosphate synthase, which is part
of the mevalonate pathway. Consequently, BPs inhibit the
activation of small G-proteins such as Ras, Rap1, and Rho, and
reduce the signals necessary for cancerous progressions, which are
transduced by these proteins (Kuroda et al, 2003; Nogawa et al,
2005b; Sato et al, 2005; Yuasa et al, 2005).
To date, there has been only one study addressing the possibility
of a direct effect of BPs on growth and survival of human bladder
cancer cells. Inoue et al (2005) demonstrated relatively high
concentrated minodronic acid (YM529), which is the most potent
third-generation BP (Dunford et al, 2001), alone or in combination
with docetaxel, reduced the growth of UM-UC-14 bladder cancer
cells implanted in tibia (Inoue et al, 2005). In order to understand
the efficacy of BPs against bladder cancer thoroughly, we
investigated the activity of YM529 alone and in combination with
cisplatin or paclitaxel on various human bladder cancer cell lines
in this study. We have additionally investigated the growth
inhibitory effect of YM529 in two different mouse models. First,
in order to examine the effect of systemic administration, we used
a bone metastatic model, in which cancer cells were inoculated into
the left ventricle of the heart and spread throughout the body.
Secondly, in order to examine the effect of intravesical adminis-
tration, we used an orthotopic bladder cancer mouse model.
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sMATERIALS AND METHODS
Animals, cell lines, and reagents
Approval for these studies was obtained from the institutional
review board at Kyoto University Hospital. All in vivo procedures
met the standards required by the United Kingdom coordinating
committee on cancer research (UKCCCR) guidelines. In addition,
the animal study procedures were consistent and in accordance
with the UKCCCR guidelines for the welfare of animals in
experimental neoplasia (Workman et al, 1998). Pathogen-free 6-
to 8-week-old female SCID mice and BALB/c nu/nu mice were used
in bladder orthotopic and bone metastatic models, respectively
(Japan Clea, Osaka, Japan). The human bladder cancer cell lines,
253J, 5637, RT4, RT112, TCCSUP, KU-7, and UM-UC-3, were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD). UM-UC-3 cell was stably transfected with the
pGL3-control vector (Promega, Madison, WI, USA) and with
pSV2Neo (ATCC) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) and named UM-UC-3
LUC (Nogawa et al, 2005c). YM529,
cisplatin, and paclitaxel, were obtained from Yamanouchi (Tokyo,
Japan), Nippon Kayaku (Tokyo, Japan), and Bristol–Myers Squibb
(New York, NY, USA), respectively.
Western blot analysis
Protein samples were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then electroblotted onto a
PVDF membrane (Millipore, Tokyo, Japan), as described pre-
viously (Kuroda et al, 2003). Goat polyclonal anti-unprenylated
Rap1A antibody (diluted 1:1000) (Santa Cruz Biotechnologies,
Santa Cruz, CA, USA) and mouse monoclonal anti-Ras antibody
(diluted 1:1000) (Becton Dickinson, San Jose, CA, USA) were used
as the primary antibodies.
Determination of cell proliferation in vitro
Proliferation of the cell lines was measured by Cell Count Reagent
SF (Nacalai Tesque, Kyoto, Japan) according to the manufacturer’s
instructions. Bladder cancer cell lines were cultivated in a flat-
bottomed 96-well plate (Greiner Labortechnik, Frickenhausen,
Germany) at 3000 cells per well in 100ml of medium supplemented
with 10% fetal bovine serum and incubated with various
concentrations of YM529 alone or in combination with cisplatin
or paclitaxel for 72h. The means of six values for each treatment
were calculated. For all the cell lines, we evaluated a linear
relationship between the degree of proliferation and cell number
within the range of the experiment. Half-maximal inhibition
constants (IC50) were determined using the nonlinear regression
program CalcuSyn (Biosoft, Cambridge, UK). To investigate the
effect of combining YM529 with other anticancer agents, the cells
were treated with six concentrations (0.25, 0.5, 0.75, 1.0, 1.5, or
2.0 IC50) of each agent. Relative cell viabilities indicate the
percentile viabilities of each column compared to that of control.
To evaluate the combined effects of concurrent treatments, the
combination indexes (CI) were calculated using CalcuSyn for
Windows software (Chou 1991). This method provides the
quantitation of synergism (CIo1) and antagonism (CI41) at
different dose and effect levels. The Fraction affected (Fa) at each
dilution was calculated (i.e., Fa of 0.25 would equal 75% viable
cells).
DNA and Annexin V staining
Hoechst 33342 DNA staining (Molecular Probes, Eugene, OR,
USA) was performed according to the manufacturer’s protocol. To
detect apoptotic cells, we performed Annexin V staining using the
MEBCYTO Apoptosis Kit (Medical and Biological Laboratories
Co., Nagoya, Japan).
Mouse models
To generate a bone metastatic and an orthotopic models of bladder
cancer, UM-UC-3
LUC cells were injected into left ventricle (1 10
6/
100ml PBS) and murine bladder (2 10
6/100ml PBS), respectively,
on day 0, as described previously (Nogawa et al, 2005a,c). Tumour
growth was monitored using an in vivo imaging system (IVIS,
Xenogen, Alameda, CA, USA) with an aqueous solution of luciferin
(150mgkg
 1 intraperitoneally), as described previously (Nogawa
et al, 2005a).
In vivo effects of YM529
Bone metastasis model After injection of UM-UC-3
LUC cells, mice
were divided into two groups of 10 mice each and the mice were
then either left untreated, or were treated with 80mgkg
 1 YM529
subcutaneously once a week on days  1, 6, and 13.
Orthotopic mouse model On day 4, the mice were observed by
IVIS and the bioluminescence from implanted cancer cells was
measured. The mice were then divided into three groups of ten
mice in such a way that each group had approximately the same
average bioluminescence. The mice were then either left untreated,
or were treated five consecutive times from days 5 to 9 with 30 or
100mM (100ml) YM529 administered transurethrally.
The bioluminescence from the implanted cancer cells was
measured twice a week by IVIS. Three weeks after UM-UC-3
LUC
cell inoculation, all mice were killed humanely and their sera
were collected. The levels of the following serum components were
then determined: aspartate aminotransferase (AST), alanine
aminotransferase (ALT), lactate dehydrogenase (LDH), total
protein (TP), creatinine (Cre), blood urea nitrogen (BUN), and
calcium (Ca).
Immunohistochemical staining Immunohistochemical staining
was performed by the conventional avidin–biotin–peroxidase
complex method (ABC-Elite, Vector Laboratories, Burlingame, CA,
USA), as described previously (Nogawa et al, 2005c). The
orthotopic model mice were either left untreated, or were treated
two consecutive times from days 9 to 10 with 30mM (100ml) of
YM529 administered transurethrally, killed under sufficient
anaesthesia, and their bladder were removed at day 10. Goat
polyclonal anti-unprenylated Rap1A antibody with a 1:100 dilution
was used as the primary antibody. Sections were counterstained
with hematoxylin and mounted. Normal mouse IgG was used
instead of primary antibody as a negative control.
Statistical analysis The influence of YM529 on the growth of
bladder cancers was analysed by the Student’s t-test using Statmate
III (Atoms Co., Tokyo, Japan) statistical software. In all statistical
analyses, P-values less than 0.05 were judged to be statistically
significant.
RESULTS
Effect of YM529 on the prenylation of Ras and Rap1A in
bladder cancer cells
To determine whether YM529 inhibits protein geranylgeranylation
and/or farnesylation in bladder cancer cells as well as it blocks
these events in other cancer cells, we investigated whether YM529
prevents the prenylation of Rap1A (which is activated after
geranylgeranylation) and Ras (which is primarily activated after
farnesylation). YM529 clearly inhibited the prenylation of Rap1A
as it resulted in a time-dependent increase in unprenylated-Rap1A
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slevels (Figure 1A). However, changes in the prenylation status of
Ras were less distinct. Consequently, we examined Ras protein
levels in cytosolic and membrane fractions by Western blotting.
Ras accumulated in the cytosolic fraction and decreased in the
membrane fraction after 24h of YM529 treatment (Figure 1B)
suggesting that YM529 inhibits not only geranylgeranylation but
also farnesylation in bladder cancer cells. To determine whether
the YM529-induced inhibition of prenylation is responsible for the
growth inhibitory effect, we investigated whether the YM529-
induced growth inhibition was reversed by geranylgeraniol
(GGOH), which restores geranylgeranylation, or by farnesol
(FOH), which restores farnesylation. However, because cytotoxi-
city of GGOH and FOH hamper these experiments, we could not
determine whether YM529 inhibits geranylgeranylation and/or
farnesylation in bladder cancer cells (data not shown). These
results are consistent with the previous studies that GGOH and
FOH induce apoptosis for the several kinds of cells (Miquel et al,
1998, Wright et al, 2001).
Growth inhibition and induction of apoptosis by YM529
in vitro
Next, we investigated the ability of YM529 to inhibit the growth of
seven human bladder cancer cell lines using the 3-(4,5-dimethyl-2-
thiazolyl)-2,5diphenyl-2H-tetrazolium (MTT) assay. YM529 inhib-
ited the growth of these cells in a dose-dependent manner
(Figure 2A). The IC50 values of YM529 for growth inhibition in
these bladder cancer cell lines, 253J, 5637, RT4, RT112, TCCSUP,
KU-7, and UC-UM-3 are 12.2, 7.1, 12.2, 15.4, 21.8, 24.8, and
20.8mM, respectively. These results indicate that BPs can inhibit the
growth of bladder cancer cells, as reported previously for other
cancer cells (Kuroda et al, 2003; Nogawa et al, 2005b; Yuasa et al,
2005).
We performed DNA staining of YM529-treated bladder cancer
cells to characterize the appearance of the nucleus. Control cells
showed a diffuse homogenous staining with Hoechst 33342, but
YM529-treated bladder cancer cells showed an abnormal con-
densed chromosomal appearance, which suggested apoptotic cells
(Figure 2B). In order to confirm induction of apoptosis, we
investigated Annexin V staining on YM529-treated UM-UC-3 cells.
YM529-treated cell cultures contained abundant Annexin V-
positive apoptotic cells (Figure 2C), whereas untreated cultures
did not. These results indicate that YM529 gave rise to growth
inhibition and induced apoptosis in bladder cancer cells in vitro.A
previous study evaluating the efficacy of zoledronic acid (ZOL),
another third-generation BP, in treating osteoporosis found that
the peak serum concentrations were in the range of 1–3mM and
were maintained for only a few hours, which indicates that the
serum concentrations needed for effective anticancer activity may
be difficult to achieve (Berenson et al, 2000). However, clinically
effective concentrations of YM529 may be readily achieved in two
types of cancers, metastatic bone lesions, because of BP
accumulation in bone, and orthotopic bladder cancer, because of
the feasibility of intravesical administration of YM529 into the
bladder.
Effect of YM529 on bladder cancer growth in a bone
metastatic model
In vivo implantation of tumour cells transfected with the luciferase
gene allows sequential monitoring of tumour growth within the
0 2 6 24 48 (h)
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Figure 1 YM529 inhibits both geranylgeranylation and farnesylation in
vitro.( A) Effect of YM529 on the prenylation of Rap1A and Ras in UM-UC-
3 cells. The cells were treated with 100mM YM529 for 2, 6, 24, or 48h and
then lysates were collected and immunoblotted with antibodies specific for
unprenylated Rap1A, Ras, or Actin. (B) Alteration of cytosolic and
membrane-anchored Ras by YM529. UM-UC-3 cells were treated with
100mM YM529 for 2, 6, or 24h and cell lysates were collected, separated
into cytosolic and membrane fractions, and subjected to Western blotting
analysis using an anti-Ras antibody.
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Figure 2 YM529 demonstrates growth inhibition and apoptosis induction of bladder cancer cells in vitro.( A) Growth inhibitory effect of YM529 alone on
bladder cancer cells. Various bladder cancer cell lines were plated at 3000 cellswell
 1 in 96-well plates, incubated for 24h, and then treated with various
doses (0–100mM) of YM529. After 72h of incubation, relative cell growth was measured by a modified MTT assay. The data (n¼6) shown are the
means7s.d. (B and C) Apoptosis induction by YM529 (30mM, 48h) was identified by Hoechst 33342 DNA staining (B) or FITC-Annexin V staining (C).
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sviscera by measuring these photon signals (Adams et al, 2002;
Hollingshead et al, 2004; Uhrbom et al, 2004; Nogawa et al,
2005a,c). Therefore, we have introduced this quantitative method
into this study. Injection of cancer cells via the left ventricle is an
established method of inducing bone metastases (Mundy, 2001).
When we introduced UM-UC-3
LUC cells by intracardiac injection,
we found the sites of metastasis and the spreading patterns were
reasonably consistent with other cell lines. We monitored the
growth of bone metastasis in lesions of maxilla and bilateral hip
joints (Figure 3A). Moreover, we evaluated the efficacy of YM529
against visceral metastases by measuring the photon counts of the
metastatic lesions in female genitalia and accessory organs
(Figure 3B). First, we pathologically confirmed bone metastatic
lesion (Figure 3C). The growth of the bone metastatic lesions in
YM529-treated mice was significantly less than that of untreated
mice (Po0.001) (Figure 3D). YM529 showed a tendency to inhibit
the growth of visceral metastases, but the effect was not significant
(Figure 3E). The body weights and serum components of the two
groups of mice did not differ significantly (Table 1). These results
suggested YM529 successfully prevented the growth of bone
metastases without any adverse side effects, but failed to prevent
the growth of visceral metastases. In addition, although we tried to
re-estimate the metastatic bone lesions, which we found apparently
by IVIS, we could not detect the lesions by CT scan clearly
(Supplemental Figure), so we gave up to observe the metastatic
bone lesions by CT scan.
In vitro combined effects of YM529 and chemotherapeutic
agents
YM529 suppressed bladder cancer cell growth in vivo, but did not
completely inhibit tumour growth. Our previous studies indicated
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Figure 3 Growth inhibition of bladder cancer by subcutaneous injection of YM529 in a bone metastatic bladder cancer mouse model. (A and B)T o
evaluate the effect of YM529 on UM-UC-3
LUC cell growth in vivo, we selected three metastatic lesions, the maxilla, and hip joints as examples of bone
metastasis (A) and a lower abdominal lesion as an example of visceral metastasis (B), and measured their photon emissions by IVIS. Images were obtained
by IVIS at 1 and 3 weeks after transplantation of cells by intracardiac injection. The photon counts of each mouse are indicated by the colour scales. (C)
Hematoxilin/eosin staining of the bone metastasis of UM-UC-3
LUC cells in the bone and bone marrow. (D and E) Average real-time growth curves of UM-
UC-3
LUC cells of bone metastatic lesions (D, upper) and the visceral metastatic lesion (E, upper) in YM529-treated mice and control-untreated mice.
Photon emissions of UM-UC-3
LUC cells in the mandible and hip joints (D, lower) and lower abdomen (E, lower) of YM529- treated and untreated mice on
day 21 are shown. YM529 significantly prevented the growth of metastatic bone lesions (Po0.001), but not of visceral metastasis. Closed circle: no
treatment, open circle: YM529 treatment.
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sthat BPs augment the effects of several anticancer agents in
leukaemia cells (Kimura et al, 2004). Therefore, we investigated the
use of combinations of YM529 and other chemotherapeutic agents
to inhibit the growth of bladder cancer cell lines. Currently, the
primary anticancer agent used clinically for bladder cancer is
cisplatin and the leading alternative is paclitaxel. The cisplatin and
paclitaxel IC50s for cell growth in KU7, RT112, and UM-UC-3 cells
were 183 and 0.00207mM, 266 and 0.00375mM, and 62.9 and
0.00570mM, respectively. The combined effects of YM529 and
cisplatin or paclitaxel in KU7, RT112, and UM-UC-3 cells are
summarised in Table 2. Combination indexes at Fa 0.5 of cisplatin
in RT112 and UM-UC-3 and paclitaxel in UM-UC-3 and those at Fa
0.9 of cisplatin in KU7 and RT112 and paclitaxel in RT112 were
less than 1.0, indicating synergism. Thus, suggesting that systemic
YM529 may be useful for bladder cancer treatment in combination
chemotherapy.
Effect of YM529 on bladder cancer growth in an orthotopic
mouse model
YM529 may also be very useful for treatment of bladder cancer, as
the drug could be administered directly as an intravesical agent.
Before beginning in vivo trials, we confirmed that a pulse of YM529
could inhibit growth in cancer cell lines. Relatively high
concentrations of YM529 (100mM) successfully prevented the
proliferation of cancer cells even when applied for as little as 1 or
2h. The relative cell viabilities of 253J, RT112, and UM-UC-3
treated with 100mM of YM529 for 1 and 2h, as compared to
untreated control cells, were 0.26870.007 and 0.0071770.00115,
0.26970.036 and 0.16070.037, and 0.20370.016 and 0.1527
0.009, respectively (Figure 4A). We confirmed that a pulse treatment
of YM529 successfully prevented the geranylgeranylation of
Rap1A in cancer cells, even when applied for as little as 2h
(Figure 4B). The bladder is an ideal target for anticancer agents as
they can be given in the high doses often required to produce local
cellular effects, with little risk of systemic toxicity. In order to
investigate the effect of intravesical YM529 delivery, we used an
orthotopic mouse model in which 2 10
5 UM-UC-3
LUC cells were
implanted into the bladder, as described previously (Nogawa et al,
2005c). First we pathologically confirmed the successful implanta-
tion of UM-UC-3
LUC bladder cancer cells in murine bladder
(Figure 4C). Then, we investigated the alteration of Rap1A status in
bladder cancer cells by YM529. Immunohistochemical staining of
unprenylated Rap1A was apparently induced by intravesical
YM529 treatment compared to the control (Figure 4D). These
results suggested transurethrally administered YM529 inhibited
the prenylation of Ras-related proteins and the signals they
mediated in the bladder cancer cells. After the implantation,
bioluminescence was not detectable on the day following
implantation, but was detected 5 days later, and then increased
substantially for up to 3 weeks (Figure 4E). Using this orthotopic
mouse model, we investigated the efficacy of intravesical YM529
against bladder cancer. We introduced 30 or 100mM of YM529
(100ml) intravesically, and both significantly inhibited bladder
tumour cell growth (Figure 4F), although two of 10 mice from the
100mM YM529-treated group died shortly after intravesical YM529
was administered. Figure 4G demonstrates that by day 24, the
inhibitory effects of both 30 and 100mM YM529 were statistically
significant compared to the untreated mice (Po0.01). Although a
pulse treatment of 30mM YM529 could not inhibit growth in cancer
cell lines in vitro, daily intravesical treatment (from days 5 to 9,
five times) of YM529 gave rise to growth inhibition of the bladder
cancer in the lower dose treatment.
To determine the side effects of these treatments, we examined
body weight during the treatment period and the serum
concentrations of AST, ALT, LDH, TP, Cre, BUN, and Ca on day
21 after cell implantation. We did not detect any adverse effect on
body weight or the serum components tested (Table 1). We
assumed that the two mice that died suffered from mechanically
induced renal toxicity owing to the implanted bladder cancer, and
not a chemically induced side effect of YM529.
DISCUSSION
This study demonstrates that a third-generation BP, YM529, has a
direct effect on the in vitro proliferation of bladder cancer cells and
on bone metastases and orthotopic bladder cancer in vivo.
Currently, the systemic combination chemotherapy MVAC is the
standard therapy and results in long-term survival in some
patients with advanced metastatic disease, although the survival
rates are limited. To improve the current therapies for these
cancers, clinical trials with several new promising agents have been
undertaken. Among these new agents, paclitaxel is the most
active single agent in advanced urothelial cancer. A Phase II
study of paclitaxel and cisplatin for advanced urothelial cancer
Table 1 The serum variables on day 21 after cell implantation
Group AST (IUl
 1) ALT (IUl
 1) LDH (IUl
 1)T P ( g d l
 1) BUN (mgdl
 1) Cre (mgdl
 1)C a ( m g d l
 1)
Bone metastasis model
Control 95.0724.6 23.879.6 868.97213.6 4.7970.24 41.8720.9 0.1470.02 9.870.4
YM529 70.977.7 21.174.1 562.5789.6 5.1470.31 31.171.7 0.1170.01 10.170.3
Bladder orthotopic model
Control 110.6728.0 23.573.5 663.37146.0 4.8170.81 29.473.88 0.0870.01 10.170.4
YM529 30mM 108.6722.1 19.674.7 653.87131.4 5.1870.09 30.576.31 0.0870.01 9.770.2
YM529 100mM 95.8716.3 23.573.8 560.77112.1 4.9670.39 33.273.60 0.0870.01 9.670.4
Abbreviations: ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; BUN¼blood urea nitrogen; Ca¼calcium; Cre¼creatinine; LDH¼lactate dehydrogenase;
TP¼total protein.
Table 2 CI at Fa of 0.5 and 0.9 of YM529 in combination with cisplatin
and paclitaxel in bladder cancer cells
Cell Agents CI at Fa 0.5 Effect CI at Fa 0.9 Effect
KU-7
Cisplatin 1.107 Additive 0.696 Synergistic
Paclitaxel 1.066 Additive 0.914 Synergistic
RT112
Cisplatin 0.736 Synergistic 0.794 Synergistic
Paclitaxel 0.844 Additive 1.227 Additive
UM-UC-3
Cisplatin 0.878 Synergistic 1.044 Additive
Paclitaxel 0.555 Synergistic 1.135 Additive
CI¼Combination indexes; Fa¼fraction affected.
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sdemonstrated partial regression in 38% of patients and complete
regression in 32% with no major side effects (Burch et al, 2000).
However, visceral metastases including bone metastases were
predictors of a poor prognosis (Bellmunt et al, 2002).
BPs are well-known agents that significantly reduce adverse
skeletal events including pathologic fracture, spinal cord compres-
sion, hypocalcaemia, and severe pain in patients with various
malignancies (Ibrahim et al, 2003; Lipton et al, 2004; Saad et al,
2004). On the basis of results from three large, randomised, Phase
III clinical trials enrolling more than 3000 patients, ZOL (4mg via
15-min infusion) was approved in the United States for treatment
of patients with documented bone metastases from solid tumours
in conjunction with standard antineoplastic therapy (United States
Food and drug administration, 2002).
BPs inhibit protein prenylation and demonstrate direct anti-
cancer effects in various cancer cell lines (Green, 2004; Santini et al,
2006). Although the clinical effects of BPs against bladder cancer
has not been reported, recent report demonstrated that a patient with
an acute panmyelosis or bone metastasis of renal cell cancer obtained
complete remission with intravenous administrated BP alone
(Espanol et al, 2004; Michaelson et al, 2004), suggesting its potential
role as an anticancer agent. Here, we found that YM529 blocks the
prenylation of Rap1A and Ras in bladder cancer cells, inhibits the
growth of bladder cancer cells in vitro (Figures 1A, B and 2A), in a
dose- and time-dependent manner, and clearly induces apoptosis in
bladder cancer cells (Figure 2B). In the study of leukaemia, we
demonstrated that the efficacy and mechanism of action of the
anticancer agents YM529 and ZOL were comparable (Segawa et al,
2005). These results suggested that third-generation BPs including
YM529 and ZOL may be potent antibladder cancer agents.
Consequently, we investigated the growth inhibitory effect of
YM529 in a mouse model, namely, a left-ventricular implanted
bone metastatic model. Despite the marginal growth inhibition of
visceral metastases, treatment with YM529 had a significant
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Figure 4 Growth inhibition of bladder cancer by transurethral injection of YM529 in an orthotopic bladder cancer mouse model. (A) Comparison of in
vitro growth inhibition of bladder cancer cells by pulse treatment with YM529 with different treatment times. Relative cell growth was measured 72h after
the initiation of treatments. Bars indicate s.d. (B) Alteration of Rap1A prenylation in UM-UC-3 bladder cancer cells by pulse treatment with YM529 for
different treatment times. The cells were treated with 100mM YM529 for 2, 6, or 24h and then lysates were collected and immunoblotted 24h after the
initiation of treatments. (C) Hematoxilin/eosin staining of the transurethral implantation of UM-UC-3
LUC cells in the murine bladder. (D)
Immunohistochemical study revealed unprenylated Rap1A was apparently induced in the cytoplasms of the bladder cancer by intravesical YM529
treatment compared to the control. (E) Intravesical growth of bladder cancer in an orthotopic mouse model. Images were obtained by IVIS at 1 day, 1 week,
2 weeks, and 3 weeks following implantation of UM-UC-3
LUC cells. The photon counts of each mouse are indicated by the colour scale. (F) Average real
time growth curves of intravesical UM-UC-3
LUC cells in mice treated with 30 or 100mM YM529 and in untreated mice. Closed circle: no treatment, open
circle: YM529 30mM, closed triangle: YM529 100mM.( G) Photon emissions of intravesical UM-UC-3
LUC cells of YM529- treated and untreated mice on day
24 are shown. Transurethral administration of both 30 and 100mM YM529 prevented the intravesical growth of bladder cancer (Po0.01).
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(Figure 3E and F). The low efficacy of YM529 against visceral
metastases may reflect the fact that it is difficult to achieve
therapeutically effective serum concentrations (1–3mM) of YM529
in vivo. However, BP has a high affinity for mineralised bone and
rapidly localizes to the bones. The concentration of BP in bone
tissue reached as high as 800mM in osteoclast bone (Sato et al,
1991). Thus, YM529 may directly promote apoptosis in bone
metastatic tumour cells. Although we have not directly measured
YM529 concentrations in bone and bone marrow, YM529 clearly
has anticancer effects in vivo.
Another possible mechanism of bone metastatic model is the
indirect in vivo growth inhibition through the inhibition of
osteoclastgenesis. Bisphosphonates exhibit a high affinity for
calcified matrices such as hydroxyapatite in bone, and promote
the induction of apoptosis in osteoclasts (Hughes et al, 1995). Bone
is an abundant repository for immobilized growth factors,
including transforming growth factor b, fibroblast growth factor,
insulin-like growth factors I and II, platelet-derived growth factor,
and bone morphogenic proteins (Roodman, 2004). When the
osteoclasts absorb bone by secreting proteases, these growth
factors are released and provide fertile ground in which tumour
cells can grow. Thus, BPs can reduce bone resorption mediated by
osteoclast and make a less favourable site for tumour cell growth.
It is critical to know whether the levels that were achieved in
these animals are ever likely to be achievable in humans. In
orthotopic model, the intravesical concentration would be clearly
achievable and the inhibitory mechanism of vesico-ureteral reflux
can be worth inhibiting renal toxicity. In bone metastatic model,
the concentration of BPs in bone tissue also would be achievable
because the concentration of BP in bone tissue reached as high
as 800mM in osteoclast bone (Sato et al, 1991). Furthermore,
the dosage of YM529 that we injected subcutaneously
(80mgkg
 1week
 1 for 3 weeks) was comparable to the dosage
used in Phase I clinical study. Peroral 9mg of YM529, whose
bioavailability was estimated approximately 1%, was administrated
to the patients with multiple myeloma daily. Moreover, the
concentration that we used was one-third the concentration of
the previous renal cancer model. No harmful effects were detected
in the renal cancers models (Yuasa et al, 2005), nor were adverse
reactions apparent in the current study (Table 1). Inoue et al
(2005) found the growth inhibitory effect of YM529 on UM-UC-14
bladder cancer cells implanted in tibia. They administered YM529
(0.3mgkg
 1), once a week for 4 weeks intraperitoneally. The total
dose they used are five times more than ours. Thus, the dosage we
used may be safe and likely to be achievable in the patients with
bladder cancer as well.
Mortality in most cancer patients is increasingly linked to
metastatic disease. Bone is the third most common metastatic site
of bladder cancer (Messing, 2001), and is infrequently cured by
current chemotherapeutic regimens. We investigated YM529 as a
therapeutic partner for cisplatin and paclitaxel because these two
agents are the central agents in combination chemotherapies for
bladder cancer (Burch et al, 2000; Dreicer, 2001). YM529
demonstrated good synergistic or additive antiproliferative effects
when administered in combination with cisplatin or paclitaxel on
three human bladder cancer cell lines (Table 2). These results are
consistent with many other studies against a range of tumour cell
lines (Jagdev et al, 2001; Kimura et al, 2004; Matsumoto et al,
2005). We speculate that addition of BPs to existing chemo-
therapeutic regimens, as exemplified by MVAC plus ZOL therapy,
might improve the effectiveness of the treatment.
Finally, we investigated intravesical administration against an
orthotopic bladder cancer model, as local administration of YM529
in the restricted environment of the bladder could provide a high
concentration exposure of the agent to the target cancer cells over
a limited time. High concentrations of YM529 had significant
anticancerous effects with a pulse treatment (Figure 4A and B).
Intravesical Bacillus Calmette-Guerin (BCG) treatment, which is
currently the most effective therapy for bladder cancer treatment,
causes irritative voiding symptoms in 90% of cases owing to
inflammation, which may be necessary for the effective action of
this agent. Moreover, BCG sepsis, although rare (0–4%), is a life-
threatening condition (Messing, 2001). Options are especially
needed for patients who are refractory to intravesical BCG. In this
study, we demonstrated that intravesical YM529 (both 30 and
100mM) successfully prevented growth of bladder cancers (Figure
4F and G), thus demonstrating its effectiveness as a potent
chemotherapeutic agent.
In conclusion, YM529 is a third-generation BP with anticancer
activity against bladder cancer both in vitro and in vivo. YM529
demonstrated good synergistic or additive antiproliferative effects
when administered in combination with cisplatin and paclitaxel.
This indicates that YM529 may be a promising therapeutic strategy
for bladder cancer. Recently, the US Food and Drug Administra-
tion approved several BPs to treat not only osteoporosis, but also
cancer-related bone complications (United States Food and drug
administration, 2002). The efficacy and safety of BP as an agent for
combination chemotherapy against bladder cancer should be
verified by early-phase clinical trials.
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